Abstract | OBJECTIVES: Since 2004, uterine fibroids have been treated with MR-HIFU, but there are persevering doubts on long-term efficacy to date. In the Focused Ultrasound Myoma Outcome Study (FUMOS), we evaluated long-term outcomes after MR- HIFU therapy, primarily to assess the reintervention rate. METHODS: Data was retrospectively collected from 123 patients treated with MR-HIFU at our hospital from 2010 to 2017. Follow-up duration and baseline (MRI) characteristics were retrieved from medical records. Treatment failures, adverse events, and the nonperfused volume percentage (NPV%) were determined. Patients received a questionnaire about reinterventions, recovery time, satisfaction, and pregnancy outcomes. Restrictive treatment protocols were compared with unrestrictive (aiming for complete ablation) treatments. Subgroups were analyzed based on the achieved NPV < 50 or ≥ 50%. RESULTS: Treatment failures occurred in 12.1% and the number of adverse events was 13.7%. Implementation of an unrestrictive treatment protocol significantly (p = 0.006) increased the mean NPV% from 37.4% [24.3-53.0] to 57.4% [33.5-76.5]. At 63.5 ± 29.0 months follow-up, the overall reintervention rate was 33.3% (n = 87). All reinterventions were performed within 34 months follow-up, but within 21 months in the unrestrictive group. The reintervention rate significantly (p = 0.002) decreased from 48.8% in the restrictive group (n = 43; follow-up 87.5 ± 7.3 months) to 18.2% in the unrestrictive group (n = 44; follow-up 40.0 ± 22.1 months). The median recovery time was 2.0 [1.0-7.0] days. Treatment satisfaction rate was 72.4% and 4/11 women completed family planning after MR-HIFU. CONCLUSIONS: The unrestrictive treatment protocol significantly increased the NPV%. Unrestrictive MR-HIFU treatments led to acceptable reintervention rates comparable to other reimbursed uterine-sparing treatments, and no reinterventions were reported beyond 21 months follow-up. KEY POINTS: • All reinterventions were performed within 34 months follow-up, but in the unrestrictive treatment protocol group, no reinterventions were reported beyond 21 months follow-up. • The NPV% was negatively associated with the risk of reintervention; thus, operators should aim for complete ablation during MR-guided HIFU therapy of uterine fibroids. • Unrestrictive treatments have led to acceptable reintervention rates after MR-guided HIFU therapy compared to other reimbursed uterine-sparing treatments.
|
Authors | Inez M Verpalen, Jolien P de Boer, Marlot Linstra, Roelien L I Pol, Ingrid M Nijholt, Chrit T W Moonen, Lambertus W Bartels, Arie Franx, Martijn F Boomsma, Manon N G Braat |
Journal | European radiology
(Eur Radiol)
Vol. 30
Issue 5
Pg. 2473-2482
(May 2020)
ISSN: 1432-1084 [Electronic] Germany |
PMID | 32040725
(Publication Type: Journal Article)
|
Topics |
- Adult
- Clinical Protocols
- Female
- Follow-Up Studies
- High-Intensity Focused Ultrasound Ablation
(methods)
- Humans
- Leiomyoma
(surgery)
- Magnetic Resonance Imaging, Interventional
(methods)
- Male
- Middle Aged
- Myoma
(diagnosis, therapy)
- Retrospective Studies
- Surveys and Questionnaires
- Time Factors
- Treatment Outcome
- Uterine Neoplasms
(diagnosis, surgery, therapy)
|